Home » Stocks » RCKT

Rocket Pharmaceuticals, Inc. (RCKT)

Stock Price: $31.85 USD 0.89 (2.87%)
Updated December 1, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.76B
Revenue (ttm) n/a
Net Income (ttm) -98.64M
Shares Out 55.23M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $31.85
Previous Close $30.96
Change ($) 0.89
Change (%) 2.87%
Day's Open 31.30
Day's Range 30.56 - 31.99
Day's Volume 299,766
52-Week Range 9.71 - 34.68

More Stats

Market Cap 1.76B
Enterprise Value 1.60B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 55.23M
Float n/a
EPS (basic) -1.82
EPS (diluted) -1.82
FCF / Share -1.90
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.14M
Short Ratio 30.47
Short % of Float n/a
Beta 1.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.11
Revenue n/a
Operating Income -94.72M
Net Income -98.64M
Free Cash Flow -104.66M
Net Cash 161.91M
Net Cash / Share 2.93
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -18.63%
ROE -41.64%
ROIC -43.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (12)

Buy 11
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$39.60*
(24.33% upside)
Low
34.0
Current: $31.85
High
47.0
Target: 39.60
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-76.15-71.16-19.77-7.57-20.40-7.70-6.65-5.85
Net Income-77.27-74.52-19.58-7.57-67.98-9.53-7.62-6.06
Shares Outstanding49.0139.386.806.834.580.260.250.25
Earnings Per Share-1.58-1.89-2.88-1.11-14.88-54.08-40.20-32.16
Operating Cash Flow-64.66-53.79-15.96-5.50-17.42-9.74-6.46-6.94
Capital Expenditures-23.27-1.43-0.76-0.34-0.41---
Free Cash Flow-87.93-55.22-16.72-5.84-17.83-9.74-6.46-6.93
Cash & Equivalents30620818.351261113.6212.791.37
Total Debt47.4541.45-48.96-7.156.812.71
Net Cash / Debt25916618.3577.51111-3.545.99-1.34
Assets37225120.151301135.5212.861.42
Liabilities64.8257.284.6356.484.5110.2810.533.79
Book Value30719415.5273.17109-51.56-38.90-30.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rocket Pharmaceuticals, Inc.
Country United States
Employees 84
CEO Gaurav Shah

Stock Information

Ticker Symbol RCKT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RCKT

Description

Rocket Pharmaceuticals, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.